Life Technologies Acquires Compendia Bioscience

               Life Technologies Acquires Compendia Bioscience

-Bioinformatics expertise will enable deeper engagement with established
customer base of leading pharmaceutical companies

-Positions Life Technologies as a partner of choice for drug and companion
diagnostic development

-Acquisition completes the foundation of Life Technologies' oncology strategy

PR Newswire

CARLSBAD, Calif., Oct. 8, 2012

CARLSBAD, Calif., Oct. 8, 2012 /PRNewswire/ --Life Technologies (NASDAQ:
LIFE) today announced the acquisition of Compendia Bioscience, a preeminent
cancer bioinformatics company widely used by the pharmaceutical industry to
identify novel gene targets for drug discovery and development. Its deep
oncology expertise and high-value, proprietary assets enhance Life's
diagnostic development capabilities across multiple platforms, including
next-generation sequencing, qPCR and proteome analysis.

Compendia's existing business, which will continue under the leadership of its
current management team, adds an established base of pharmaceutical industry
customers for Life Technologies' platforms. Compendia's oncology data is
widely utilized by leading pharmaceutical companies in their drug development
work and will extend Life's abilities to both develop its own tests and to
partner with pharmaceutical companies in companion diagnostic development.

"We have created the optimal foundation to drive progress in personalized
medicine," said Gregory T. Lucier, Chairman and Chief Executive Officer of
Life Technologies. "By combining the acquisitions of Pinpoint Genomics,
Navigenics and Compendia, we now possess the full spectrum capability to
develop and commercialize high-value cancer diagnostics where there is
currently great unmet need."

The recent launch of Pervenio™ Lung RS, a first-of-its-kind prognostic test,
underscores Life Technologies' strategy to focus initially on lung cancer,
ahighly underserved disease. The company plans to utilize the extensive
content in Compendia to springboard to other areas of oncology.

Preeminent Assets Widely Used by Leading Pharmaceutical Companies
Compendia holds one of the world's largest and most comprehensive sets of
mutation profiles, gene expression data and cellular biomarkers that have been
gathered from more than 62,000 cancer patients. Oncomine™, the company's
cloud-based analytics tool, integrates high-throughput cancer profiling data
across a large volume of cancer types to allow users to mine it for
correlations among genetic signatures, clinical status, and drug response

The proprietary technology is especially useful to Compendia's
well-established pharmaceutical customer base. They use it to ascertain the
genes most frequently mutated across thousands of samples of a given cancer
type, as well as the biomarkers associated with biological responses to
specific classes of compounds. Equally valuable is Compendia's OncoScore™
product, a tool that helps optimize the clinical trials process by stratifying
patients based on genetic signatures so that individuals most likely to
respond to specific drugs are included.

"Compendia has become an integral part ofthe pharmaceutical industry's cancer
drug discovery programs, and in joining Life Technologies, we'll gain the
opportunity to expand the utility of Compendia even further," said Daniel R.
Rhodes, Compendia's Chief Executive Officer and co-founder, who will join Life
Technologies following the acquisition.

Compendia co-founder Arul Chinnaiyan, M.D., Ph.D., a pioneer in the field of
cancer research, will serve as strategic advisor to Life Technologies, helping
to shape the company's further steps into personalized medicine.

Cancer Biology Expertise Enhances Life's Diagnostics Development Capability
"Compendia is highly regarded by its customers as a preeminent source of
cancer biology expertise," said Ronnie Andrews, President of Medical Sciences
at Life Technologies. "That expertise will serve as a content engine to drive
development of diagnostic content across the breadth of Life platforms.

"Initially, tests like Pervenio™ Lung RS, will be offered as a service through
our CLIA laboratory, but our longer-term goal is to commercialize diagnostic
products on Life platforms for use in hospitals labs, where the majority of
patients are treated," Andrews said. "All patients should have access to an
opportunity to benefit from the extensive knowledge base that has been gained
through decades of research."

In addition to enabling Life Technologies' ability to develop its own
lab-developed and commercial tests, the Compendia acquisition will enhance
Life's companion diagnostics effort and positions the company as a partner of
choice for pharma. Life can now offer best-in-class products and services for
target discovery and validation, biomarker analysis, clinical sample testing,
companion diagnostics development and clinical implementation.

Life Technologies plans to develop a clinical version of Oncomine™, which will
allow physicians to compare their patients' genetic signatures against large
data sets to determine the most effective drug protocols. A seamless transfer
of the bioinformatics data into easy-to-use, actionable information will be
possible with the treating physician portal repurposed from the Navigenics

Life Technologies will also incorporate the Compendia oncology workflow within
its Ion Reporter™ software to accelerate its lead in building the most robust
bioinformatics offering in the industry. Researchers sequencing tumor samples
on the Ion Personal Genome Machine (PGM™), for example, will be able to
leverage the insight gained from the thousands of samples already in
Compendia's database in an effort to identify targetable mutations.

The acquisition represents another significant step in Life Technologies'
strategy to develop its medical sciences business through internal
development, partnerships and select acquisitions.The financial terms of the
deal are not being disclosed. The acquisition of Compendia Bioscience is
expected to be neutral to 2012 earnings and accretive to the company's overall
ROIC by 2015.

Ion Reporter™ and Ion Personal Genome Machine™ are Research Use Only and not
intended for use in diagnostic procedures.

About Life Technologies
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied Biosystems®,
Invitrogen™, GIBCO®, Ambion®, Molecular Probes®, Novex®, and TaqMan®. Life
Technologies employs approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of $3.7 billion in 2011. Visit us at our website:

Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.


Life Technologies Contact
Suzanne Clancy
858-205-4235 (mobile)

SOURCE Life Technologies

Press spacebar to pause and continue. Press esc to stop.